Swedish Orphan Biovitrum AB (publ)

SOBI · Nasdaq Stockholm · Healthcare

427.80SEK −1.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: +49.2%

Performance

1 month

−7.0%

1 year

+49.2%

3 years, per year

+24.7%

5 years, per year

+13.5%

Largest fall, 3 years

−28.8%

Below the peak now

−10.9%

Volatility, 1 year

28.0%

Return with dividends reinvested.

Key figures

P/E

104.6

P/B

3.4

Dividend yield

0.0%

Return on equity

+3.3%

Net margin

+4.5%

Market value

14.9 bn USD

Quality, value and trend

Where Swedish Orphan Biovitrum stands against every Nordic stock today. 100 is best.

Quality59

Profitability and a sound balance sheet over time. Better than 59% of Nordic stocks.

Value20

The price measured against earnings, assets and cash flow. Better than 20% of Nordic stocks.

Trend63

The price development over the past year. Better than 63% of Nordic stocks.

Combined41

Quality, value and trend together. Better than 41% of Nordic stocks.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2,100 employees.

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemo…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis